Specialty pharmacy: The topic that won t stop growing.

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "Specialty pharmacy: The topic that won t stop growing."

Transcription

1 Specialty pharmacy: The topic that won t stop growing. Employee Benefits Planning Association Grant Knowles, PharmD, CSP Ardon Health Specialty pharmacy Vice President of Operations June 4 th, 2015

2 Overview

3 Healthcare spending (past and future) $6,000 53% Billions $5,000 $4,000 $3,000 $2,298 $2,501 $2,701 $2,915 $3,273 $3,660 $4,142 $4,702 $2,000 $1,000 $0 CMS. National Health Expenditure Projections Trends-and-Reports/NationalHealthExpendData/downloads/proj2012.pdf

4 Prescription spending (past and future) % 426 Billions CMS. National Health Expenditure Projections CMS. National Health Expenditures Aggregate, Per Capita Amounts, Percent Distribution, and Average Annual Percent Growth: Selected Calendar Years

5 Patent cliff generic relief $90 billion dollars in reduced spend over the last 5 years

6 Patent cliff generic relief Brand name (generic name) Uses Retail sales ($Mil) Lipitor (atorvastatin) High cholesterol 5,803 Plavix (clopidigrel) Prevention of arterial thrombotic events 5,020 Singulair (montelukast) Asthma, allergic rhinitis 3,823 Seroquel (quetiapine) Schizophrenia, bipolar disorder 3,549 Actos (pioglitazone) Type 2 diabetes 2,913 Cymbalta (duloxetine) Depression, fibromyalgia, chronic pain, diabetic peripheral neuropathy 2,891 Lexapro (escitalopram) Depression 2,590 Zyprexa (olanzapine) Schizophrenia, bipolar disorder 2,114 Concerta (methylphenidate ADHD 1,560 extended-release) Levaquin (levofloxacin) Bacterial infections 1,542 Diovan (valsartan) Hypertension, CHF 1,430 Diovan HCT (valsartan/hctz) Hypertension 1,430 TriCor (fenofibrate) Hypotriglyceridemia 1,123 Lidoderm (topical patch) Post-herpetic neuralgia 1,066 Geodon (ziprasidone) Schizophrenia 1,058 Provigil (modafinil) Narcolepsy, idiopathic hypersomnolence 1,014 Aciphex (rabeprazole) GERD, stomach ulcers 1,006 *First-time generics are subject to significant change as a result of multiple patent protections, patent litigation, pediatric or other exclusivities, at-risk launches, and delays between patent expiration and launch of first-time generics. IMS retail claims data [database online]. Fairfield, CT: IMS Health;

7 Specialty prescriptions An undeniable and growing proportion of healthcare spend.

8 Defining

9 What is specialty medication? Certain pharmaceuticals, biotech, or biological drugs, which may be offered by PBM*, that are used in the management of chronic or genetic disease, including but not limited to injectable, infused, or oral medications, or products that otherwise require special handling. *PBM - Prescription Benefit Manager Chan, L (2009). Control Specialty Drug Cost By Making Your PBM Helpful. Managed Care.

10 Specialty medications 1% of prescriptions 25-35% of prescription spend 15-25% increase per year x 3 years 8 out of the top 10 medications in out of the top 10 prescription in 2022 Cost $311 PMPY in 2014 $7,000 - $400,000/member/treatment year 28 times more costly than non-specialty Drug Trend Report Express Script EvaluatePharma. World Preview

11 Specialty Parameters High Cost Complex admin Unique monitoring Specific climate needs Require additional patient education Require 24/7 clinical support Drugs not available in retail settings $1,000- $40,000 per Rx Injection, infusion REMS*, efficacy criteria Specific storage or shipment protocol hightouch disease states, adherence High sideeffects, adherence assistance LDD ± *REMS Risk Evaluation and Mitigation Strategies ± LDD Limit Distribution Drugs

12 How payers define specialty High Cost Requiring special monitoring Treats orphan disease Requires specialty handling Limited distribution Indicated for disease already classified as specialty 85% 81% 71% 73% 67% 66% Requires patient admin training From 91 payers with over 124 million lives EMD Serono Injectable Digest (10 th Edition). 43% 0% 20% 40% 60% 80% 100%

13 How payers define high cost 45% 40% 40% 35% 30% 29% 25% 20% 15% 10% 5% 14% 17% 0% From 91 payers with over 124 million lives EMD Serono Injectable Digest (10 th Edition). <$600 $600-$800 $ >$1,200

14 Past & Future

15 Spending on traditional therapies will grow at slower rates. Specialty spend will experience hand-over-fist growth in the foreseeable future.

16 Specialty spend $140 $120 $ in Billions $124 $100 $80 $60 $40 $20 $55 $1.7 trillion spend by Specialty 2030, Spend estimates PCMA $ IMS - Medicines Use and Spending Shifts April, 2015 PCMA - Pharmaceutical Care Management Association

17 Towering trends 25.0% 20.0% 22.6% 22.3% 21.3% 15.0% 10.0% 9.0% 10.3% 10.9% 5.0% 3.9% 4.3% 0.0% -5.0% -0.5% Traditional Specialty Overall Drug Trend Report 2014 Express Script

18 Price of medications PMPY $800 $700 $669 $665 $691 $721 $600 $566 $500 $400 $300 $311 $381 $466 $200 $100 $ Traditional Specialty Drug Trend Report 2014 Express Script

19 Top 10 medications in 2010 Medication 2009 Sales in Billions BOLD Indicate Specialty Medications *Now generic products EvaluatePharma. World Preview May Available at: Accessed August 30, Sales in Billions 1 *Plavix $5.5 $6.1 2 *Lipitor $5.6 $5.3 3 Advair $4.0 $4.0 4 *Seroquel $3.4 $3.7 5 Epogen/Procrit $3.8 $3.5 6 *Actos $3.2 $3.5 7 Abilify $3.2 $3.3 8 Enbrel $3.2 $3.3 9 *Singulair $3.0 $ Remicade $3.0 $3.0

20 Top 10 medications in 2013 Product Generic Name Company 1 Humira adalimumab AbbVie 2 Lantus BOLD Indicate Specialty Medications EvaluatePharma. World Preview insulin glargine recombinant 3 Enbrel etanercept Amgen 4 Remicade infliximab Johnson & Johnson Pharmacologic al Class Anti-tumour necrosis factor alpha (TNFa) MAb ,236 6,566 Sanofi Insulin 4,978 6,299 Tumour necrosis factor alpha (TNFa) inhibitor Anti-tumour necrosis factor alpha (TNFa) MAb 4,256 4,918 3,891 4,594 5 Rituxan rituximab Roche Anti-CD20 MAb 3,594 2,251 6 Neulasta pegfilgrastim Amgen Granulocyte colony-stimulating factor (G-CSF) Dipeptidyl peptidase IV inhibitor 3,499 2,640 Januvia/ sitagliptin 7 Merck & Co 2,946 3,255 Janumet phosphate 8 Avastin bevacizumab Roche Anti-VEGF MAb 2,780 2,130 Epogen/ 9 epoetin alfa Amgen + JNJ Erythropoietin 2,748 1,502 Procrit 10 Revlimid lenalidomide Celgene Immunomodulator 2,489 2,603

21 Top 10 medications in 2020 Product BOLD Indicate Specialty Medications EvaluatePharma. World Preview Generic Name 1 Humira adalimumab AbbVie 2 Lantus insulin glargine recombinant 3 Enbrel etanercept Amgen Company 4 Remicade infliximab Johnson & Johnson 5 Sovaldi sofosbuvir Gilead Sciences 6 Tecfidera dimethyl fumarate Pharmacological Class Anti-tumour necrosis factor alpha (TNFa) MAb ,236 6,566 Sanofi Insulin 4,978 6,299 Biogen Idec Tumour necrosis factor alpha (TNFa) inhibitor Anti-tumour necrosis factor alpha (TNFa) MAb Hepatitis C nucleoside NS5B polymerase inhibitor Nuclear factor erythroid 2-related factor (Nrf2) pathway activator 7 Nivolumab nivolumab Bristol-Myers Squibb Anti-programmed 8 Eylea aflibercept Regeneron Pharmaceuticals 9 Imbruvica ibrutinib Pharmacyclics 10 Xtandi enzalutamide Astellas Pharma death-1 (PD-1) MAb 4,256 4,918 3,891 4, , ,175-3,618 VEGFr kinase inhibitor 1,409 3,583 Bruton's tyrosine kinase (BTK) inhibitor Androgen receptor antagonist 14 3, ,337

22 Prescription spend distribution Prescription Spend in Billions 600 Billions Expected double again by Traditional Specialty Total IMS - Medicines Use and Spending Shifts April, 2015 Drug Trend Report 2014 Express Script

23 Prescription spend distribution Traditional Specialty Traditional Specialty Traditional Specialty Traditional Specialty 33% 36% 40% 43% 67% 64% 60% 57% IMS - Medicines Use and Spending Shifts April, 2015 Drug Trend Report 2014 Express Script

24 Why so special?

25 Why so special? Treatment & cures for conditions that may have had none Serious benefits and serious potential for side effects Shifting therapies to patient administered More home, less hospital Oncology Biologics typically do not face generic competition after their original patent protection has expired, thus extending high prices indefinitely

26 Fueling the growth Large patient populations New indications for existing drugs Improved efficacy Large pipeline of new drugs Novel mechanisms Trend Price increases

27 Specialty pipeline 70% FDA approvals were specialty, % of approvals in 2014 >900 biologics, for more than 100 diseases >70% for cancer, infectious diseases, autoimmune diseases, and cardiovascular disease 37% monoclonal antibodies or therapeutic proteins (e.g. Humira, Enbrel) Focus on small (orphan) populations (e.g. Sensipar, Soliris) Pharmaceutical Research and Manufacturers of America.. EMD Serono Specialty Digest, 10 th Edition

28 Acute become chronic 40% 35% 30% 25% 20% 15% Projected Percentage Increase in Cancer Survivors Between 2010 and % 30% 25% 13% 32% 10% 5% 0% Prostate Cancer Lymphoma Breast Cancer Colorectal Cancer All Types Source: Mariotto AB, Yabroff KR, Shao Y, et al. Projections of the cost of cancer care in the United States: Journal of the National Cancer Institute. 2011; 103(2):1-12

29 Growing population Millions U.S. Population 55 years and over 31.5% 28.2% 24.7% # of people % of population 35% 30% 25% 20% 15% 10% 5% 0% % of population U.S. Census Bureau, "2008 National Population Projections," August 2008.

30 Price increases 20.0% 18.0% 16.0% 14.0% 12.0% 10.0% 8.0% 6.0% 4.0% 2.0% 0.0% Average Annual Increase Since 2007/ % 17.5% 9.8% 9.8% 10.5% Copaxone Enbrel Humira Forteo Rebif

31 Where s the generics? Trick question, there aren t any

32 Size & Complexity Small molecule drugs & Proteins Small Molecule Drug Aspirin 21 atoms Large Molecule Drug hgh ~3000 atoms Large Biologic IgG Antibody ~25,000 atoms Complexity Size Bike ~21 lbs.. Car ~3000 lbs. Business Jet ~30,000 lbs. (without fuel)

33 Slow biosimilars slow to market Made available by the Patient Protection and Affordable Care Act No abbreviated approval process like small molecule drugs Must demonstrate safety, purity, and potency to reference product with: Analytical Testing Bioassays Animal studies Human clinical studies FDA Purple book No clinically meaningful differences between biologic and reference product in terms of safety, purity, and potency Interchangeable biosimilars may be substituted for the reference product by a pharmacist without intervention from the prescribing physician Applications/TherapeuticBiologicApplications/Biosimilars/ucm htm

34 Market impact - biosimilars Potential $44.2 billion reduction in spending from 2015 to 2024 New competition Reference product (brand) will not go away New delivery mechanisms Syringe vs. Pen Something cooler than what is out there First biosimilar was approved this year Zarxio to compete with Neupogen The Cost Savings Potential of Biosimilar Drugs in the United States

35 Specialty categories Rank Therapy Class Avg. Cost/Rx Medications Rx Per Inflammatory Conditions $2, Humira, Enbrel Stelara, 27 2 Multiple Sclerosis $4, Copaxone, Tecfidera, Avonex 12 3 Oncology $6, Gleevec, Revlimid, Capecitabine, Temozolomide 7 4 Hepatitis C $16, Sovaldi, Harvoni 2 5 HIV $1, Atripla, Truvada 24 6 Misc. $4, Botox, Xyrem 2 7 Growth Deficiency $3, Norditropin FlexPro, Genotropin 3 8 Hemophilia $7, Advate 1 9 Pulmonary Arterial Hypertension $4, Sildenafil, Adcirca, Tracleer 1 10 Transplant $ Azathioprine, Mycophenolate, Tacrolimus, Prograf 25 PCSK9 estimates up to$100 billion annually spend 2014 specialty spend was $124 billion Drug Trend Report Express Script 2014 Blockbuster Drugs Fill 2015 Pipeline March 2015 Bold generics or soon to be generic

36 Focus

37 Specialty Zavesca Afinitor Hepatitis C Stelara Xiaflex Anticoagulants Ilaris Revatio Sutent Rituxan Promacta Cancer Tykerb Simponi Xyrem Procrit Revlimid Sprycel

38 Focused industry % spend of top 10 specialty classes Others 11% Top 10 89% Drug Trend Report 2014 Express Script

39 Focus % Makeup Inflammatory Conditions Multiple Sclerosis Oncology Hepatitis C HIV Misc. Specialty Conditions Growth Deficiency Hemophilia Pulmonary Arterial Hypertension Transplant 4% 3% 2% 2% 2% 9% 13% 12% 17% 26% Drug Trend Report 2014 Express Script 0% 5% 10% 15% 20% 25% 30%

40 Manufacturer attention Blockbusters require smaller populations $10.3B Sovaldi (Hepatitis C) Development cost of orphan drugs can be lower with a higher anticipated return Avg. orphan drug cost per patient per year $137,782 Avg. non-orphan drug cost per patient per year $20,875 New report shows orphan drug market to reach $176 billion by EvaluatePharma. New release. October 29, 2014 Succeeding in the rapidly changing U.S. Specialty market. 14%20Specialty_Drug_Trend_Whitepaper_Hi-Res.pdf

41 Managing specialty

42 Determining value 30%, 5-year survival Displaced prior therapy and drastically improved 5-year survival to 89% in CML Improves survival by 10 days when giving with the standard of care for pancreatic cancer. Gleevec Tarceva Prior Therapy for CML $43,100 per life-year saved $410,000 per life-year saved Fojo T, Grady C. How much is life worth: cetuximab, non small cell lung cancer, and the $440 billion question. Journal of the National Cancer Institute. 2009;101(15): CML = chronic myeloid leukemia

43 Financial Assistance Non-adherence: A $300B problem Non-adherence/persistence? Not starting therapy Not continually staying on therapy Does cost mattes? Evidence: 3.8% reduction in adherence for every $10 in patient cost Patients with a cost <$100 initiate therapy: 37% more than those with >$200 14% more than with $101-$200 Patients using financial assistance: 30% more likely of achieving an medication possession rate (MPR) >80%

44 Financial Assistance Ardon Health financial assistance for 2015: Avg. medication cost: $4,652 Avg. copay/coinsurnace: $292 Avg. assistance: $278 Avg. patient out-of-pocket cost: $14 Copaxone Avonex Rebif Gilenya Betaseron Pt Cost $0 $0 $0 $0 $0 Monthly Max Annual Max $2, $12,000 - $12,000 $12,000 $9,500 Types of funding Manufacturer assistance* Need based-assistance Charitable assistance *Government programs (Medicare & Medicaid) are not eligible for most manufacturer assistance

45 Cost share burden Hepatitis C. treatment = ~$94,000 for 12- weeks Multiple Sclerosis = ~$54,000/patient/year Coinsurance Patient Pay 10% - $9,400 20% - $18,800 30% - $28,200 40% - $37,600 50% - $47,000 Coinsurance Patient Pay 10% - $5,412 20% - $10,824 30% - $16,236 40% - $21,648 50% - $27,060

46

47 Top strategies Prior Authorization (PA) Limit to evidence-based uses. FDA approved indications Off-label: national clinical guidelines & peer-reviewed articles Step-therapy for conditions with multiple evidence-based treatment modalities Requires the use of cost-effective therapies prior to initiation Value-based cost share Exclusive specialty tiering Waste Mitigation: 30-day supply on all treatments options Consider lower supplies for therapies with high discontinuation rates (15 day) Selecting preferred specialty pharmacy partner

48 Benefit design strategies Strategies implemented or will be in 12 months Limit specialty products to 30-day supply 94% Equalize cost share between RX and medical benefits Create cost share tier for specialty 58% 55% Create specialty drug benefit for all drugs 44% Implement value-based benefit design Allow 90-day supply for stable patients 23% 30% Lower cost share to improve adherence From 91 payers with over 124 million lives EMD Serono Injectable Digest (10 th Edition). 12% 0% 20% 40% 60% 80% 100%

49 Benefit design strategies Strategies implemented or will be in 12 months Develop stricter PA for some non-preferred drugs Create coverage guidelines across RX and medical benefit Require trial of 1 preferred drug before nonpreferred Select preferred drugs by indication Require trial of >1 preferred drug before nonpreferred Require trial time of preferred drug before non-preferred 91% 91% 87% 81% 72% 73% Exclude coverage of some non-preferred products From 91 payers with over 124 million lives EMD Serono Injectable Digest (10 th Edition). 52% 0% 20% 40% 60% 80% 100%

50 Specialty, Pharmacy? US population ~320 million Typical retail pharmacy dispenses: Specialty pharmacy, experience: ~0.9/RX /patient/month ~1,075 RX/week ~ specialty RX/week Specially RX s are ~1% ~11 specialty Rx/week Specialization # of US pharmacies ~67,000

51 Making it Right Right medication Right dose Right time Is it appropriate to start? Is it appropriate to continue? Is it the initiation of therapy? Is it continuation of therapy? Is it being taken it? Is it at the correct frequency? Specialty medication can make up 80% or more of a patient s health care spend

52 Proactive adherence management Provide disease specific patient education & management Reimbursement and eligibility coordination Specialty Services Provide 24/7 access to RN or pharmacist Preventative measures for drug waste, abuse and misuse Ensure appropriate dose of medication Flexible shipping distribution direct to patient s home, business, or MD First-level claims denial and appeals processing Patient-assistance programs In-office, in-home training capability Audit capabilities Benefit design, formulary support Expertise in benefit investigations, prior authorization, appeals

53 Connectivity Connecting patient s with support programs Patient receiving injection training 40% more likely to have a MPR >80% 24/7 pharmacist support Advocacy groups Medication disposal services Case management integration

54 Continued Assessment/Counseling Every fill: Proactive refill call (at least 7 days) Adherence assessment Side effect assessment Appropriateness assessment Improved adherence Better outcomes Reduced waste Decreased side effects and increased knowledge Reduced premature discontinuation Reduced additional health cost Appropriateness check Proper patient outcomes Reduce waste

55 Waste mitigation Focus Target highly discontinued medications e.g. oral oncology Limited duration efficacy medications Partial fill programs Dispensing day supply of therapy Duration of 1-3 months Increased healthcare touches Shown to save $1,000/patient Khandelwal N, Duncan I, Ahmed T, Rubinstein E, Pegus C. Impact of clinical oral chemotherapy program on wastage and hospitalizations. J Oncol Pract. 2011;14:e25s e29s. doi: /JOP

56 Compounds What is a compound? combining, mixing, or altering ingredients of a drug to create a medication tailored to the needs of an individual patient What s in the limelight? Topical pain compounds Why? High cost - $500-$10,000 AWP prices have risen substantially No MAC pricing 128% increase in trend in 2014 Intense marketing Can topical pain compounds be helpful? Limited evidence that the active ingredients, in combination, have been evaluated by the FDA for safety and/or efficacy Many include different active ingredients combining products from the same drug class time the commercially manufactured medication. What s being done Restrictions on use and/or cost. Drug Trend Report Express Script 2014

57

58

2015 Annual Convention

2015 Annual Convention 2015 Annual Convention Date: Monday, October 12, 2015 Time: 8:00 am 9:30 am Location: Gaylord National Harbor Resort and Convention Center, National Harbor 3 Title: Activity Type: Speaker: How to Create

More information

Prescription Drug Utilization and Cost Trends, 2009-2013

Prescription Drug Utilization and Cost Trends, 2009-2013 Agenda Item 7 Attachment 1 Prescription Drug Utilization and Cost Trends, 2009-2013 Pension and Health Benefits Committee October 14, 2014 Melissa Mantong, PharmD CalPERS Pharmacist Overview Trends in

More information

Drug Pricing, Repricing, Rebates, and Patient Access

Drug Pricing, Repricing, Rebates, and Patient Access Drug Pricing, Repricing, Rebates, and Patient Access Jack Hoadley, Ph.D. Health Policy Institute, Georgetown University Bipartisan Policy Center April 13, 2016 1 Credits and Notes Some of my drug policy

More information

The Basics of Pharmacy Benefits Management (PBM) 2009

The Basics of Pharmacy Benefits Management (PBM) 2009 The Basics of Pharmacy Benefits Management (PBM) 2009 Andrew Kingery Pharmacy Account Management Virginia CE Forum 2009 Course# 201719 Objectives & Introduction Provide basic components of a PBM Define

More information

Winter 2013. Changing landscapes, pipeline products and plan sponsor impact

Winter 2013. Changing landscapes, pipeline products and plan sponsor impact Winter 2013 Changing landscapes, pipeline products and plan sponsor impact Changing landscapes, pipeline products and plan sponsor impact The pharmaceutical landscape is changing as is the profile of blockbuster

More information

Overview of the Specialty Drug Trend

Overview of the Specialty Drug Trend WHITE PAPER Overview of the Specialty Drug Trend Succeeding In The Rapidly Changing U.S. Specialty Market 1 Specialty drugs are prescribed to treat complex conditions such as cancer, HIV and inflammatory

More information

THE GROWTH IN SPECIALTY DRUG SPENDING FROM 2013 TO 2014

THE GROWTH IN SPECIALTY DRUG SPENDING FROM 2013 TO 2014 THE GROWTH IN SPECIALTY DRUG SPENDING FROM 2013 TO 2014 This report was written by HealthCore, a wholly-owned and independently operated health outcomes subsidiary of Anthem, Inc. The Growth in Specialty

More information

Specialty Pharmacy. Business Plan. July 8, 2013. 2013 RUSH University Medical Center

Specialty Pharmacy. Business Plan. July 8, 2013. 2013 RUSH University Medical Center Specialty Pharmacy Business Plan July 8, 2013 Specialty Pharmaceuticals What are they? Biotech/gene-based therapy Require special handling Newer products oral or self- administered One third have REMS

More information

Retail Pharmacy Trends. Ed Escalante, VP/GM Edgar Cardona, VPS May 13, 2013 San Francisco, CA

Retail Pharmacy Trends. Ed Escalante, VP/GM Edgar Cardona, VPS May 13, 2013 San Francisco, CA Retail Pharmacy Trends Ed Escalante, VP/GM Edgar Cardona, VPS May 13, 2013 San Francisco, CA About this presentation Knowing Your Market Helps You Plan Ahead Understanding the latest retail pharmacy trends

More information

PRESCRIPTION MEDICINES: COSTS IN CONTEXT

PRESCRIPTION MEDICINES: COSTS IN CONTEXT PRESCRIPTION MEDICINES: COSTS IN CONTEXT 2015 Since 2000, biopharmaceutical companies have brought MORE THAN 500 NEW TREATMENTS AND CURES to U.S. patients In the last 100 years, medicines have helped raise

More information

February 2014 Patient Savings Program Use Analysis

February 2014 Patient Savings Program Use Analysis Providing key policy setters and decision makers in the global health sector with unique and transformational insights into healthcare dynamics derived from granular analysis of information. February 2014

More information

scriptsourcing THE NEXT 5 YEARS OF RX COSTS AND HOW THEY WILL IMPACT YOUR BOTTOM LINE ScriptSourcing Prescription Advocacy Services

scriptsourcing THE NEXT 5 YEARS OF RX COSTS AND HOW THEY WILL IMPACT YOUR BOTTOM LINE ScriptSourcing Prescription Advocacy Services scriptsourcing THE NEXT 5 YEARS OF RX COSTS AND HOW THEY WILL IMPACT YOUR BOTTOM LINE ScriptSourcing Prescription Advocacy Services Gary Becker, CEO Benefit Consultant, Risk Mitigation Expert, and Author

More information

Specialty Pharmacy: Understanding the Market and Solution. Your Goals. Presented by Chris Brown November 2009

Specialty Pharmacy: Understanding the Market and Solution. Your Goals. Presented by Chris Brown November 2009 Specialty Pharmacy: Understanding the Market and Solution Presented by Chris Brown November 2009 Your Goals What What is a Specialty is a specialty Medication? medication? Specialty drugs are injectable,

More information

Specialty Drug Management Solutions You Haven t Heard Before

Specialty Drug Management Solutions You Haven t Heard Before Specialty Drug Management Solutions You Haven t Heard Before Sarah Martin, ASA, MAAA, CEBS Vice President, Senior Pharmacy Consultant Lockton Kansas City, Missouri The opinions expressed in this presentation

More information

The Facts, Figures and Trends in U.S. Pharmaceutical Distribution Gayle C. Johnston, President, CuraScript SD Miguel Rodriguez, Senior Product

The Facts, Figures and Trends in U.S. Pharmaceutical Distribution Gayle C. Johnston, President, CuraScript SD Miguel Rodriguez, Senior Product The Facts, Figures and Trends in U.S. Pharmaceutical Distribution Gayle C. Johnston, President, CuraScript SD Miguel Rodriguez, Senior Product Manager, CuraScript SD 2015 Distribution Management Conference

More information

5/5/2015 PHARMACY WHAT S AN EMPLOYER TO DO? Current Structure Misaligned

5/5/2015 PHARMACY WHAT S AN EMPLOYER TO DO? Current Structure Misaligned PHARMACY WHAT S AN EMPLOYER TO DO? MAY 15, 2015 Debbie Doolittle Nashville, TN Pharmaceutical Spending Per Capita, 2013 vs. 2018 The US vs. the Rest of the World 1 Current Pharmacy Landscape How Did We

More information

Medical School for Actuaries. June 12, 2013. Baltimore, Maryland

Medical School for Actuaries. June 12, 2013. Baltimore, Maryland Medical School for Actuaries June 12, 2013 Baltimore, Maryland Developments in the Treatment of Conditions Treated with Specialty Mediations (Cancer, MS, RA, Hemophilia) Mark S. Matusik, PharmD Developments

More information

Understanding specialty drugs

Understanding specialty drugs Group Benefits Understanding specialty drugs What your pharmaceutical benefits plan may look like over the next decade Between 2011 and 2014, the percentage of total drug spend represented by specialty

More information

University of Nebraska Prescription Drug Program 2014

University of Nebraska Prescription Drug Program 2014 University of Nebraska Prescription Drug Program 2014 The University of Nebraska s prescription benefit program is administered by CVS Caremark, a leading national provider of prescription drug benefit

More information

An Evaluation of Specialty Drug Pricing Under the Pharmacy and Medical Benefit

An Evaluation of Specialty Drug Pricing Under the Pharmacy and Medical Benefit An Evaluation of Specialty Drug Pricing Under the Pharmacy and Medical Benefit March 2014 PREPARED BY Brenda Motheral, MBA, PhD President Corey Belken, PharmD Vice President Artemetrx Specialty Drug Solutions

More information

RMIP Prescription Plan FAQ's

RMIP Prescription Plan FAQ's RMIP Prescription Plan FAQ's A new U.S. Pharmacy Benefit Manager has been selected for January 1, 2015 - CVS/caremark. 1) Why is the RMIP changing to CVS/caremark? The Express Scripts contract ends on

More information

The High Prices of Prescription Drugs Increase Costs for Everyone

The High Prices of Prescription Drugs Increase Costs for Everyone The High Prices of Prescription Drugs Increase Costs for Everyone Individuals, Families, States, Taxpayers All Face Higher Costs Due to Rising Drug Prices Prescription drugs are one of the major drivers

More information

SPECIALTY TREND MANAGEMENT

SPECIALTY TREND MANAGEMENT SPECIALTY TREND MANAGEMENT Table of Contents Specialty drives pharmacy trend... Chapter 1 Managing price, mix and utilization... Chapter 2 Expand preferred drug strategies... Chapter 3 Cost-effective site

More information

Specialty Pharmacy Definition

Specialty Pharmacy Definition Isn t All of Special? Developing Services Presented to: 2015 ICHP Annual Meeting Presented on: September 10, 2015 Presented by: Lana Gerzenshtein, Pharm.D., BCPS The speaker has no conflicts of interest

More information

Novel Opportunities for Engagement Utilizing in House Pharmacy Services

Novel Opportunities for Engagement Utilizing in House Pharmacy Services Novel Opportunities for Engagement Utilizing in House Pharmacy Services Ray Bailey, BSPharm RPh Director of Pharmacy, FCS Rx to Go Pharmacy rbailey@flcancer.com Angel Aslo, Pharm.D. Director of Pharmacy,

More information

Biologics: Specific Drug Safety Challenges. Violetta B. Kyburz

Biologics: Specific Drug Safety Challenges. Violetta B. Kyburz Biologics: Specific Drug Safety Challenges Violetta B. Kyburz 2012 2013 2014 Biologics: Specific Drug Safety Challenges Topics for discussion Particular issues in the preclinical development of biologics

More information

The Excelsior Solutions Difference

The Excelsior Solutions Difference The Excelsior Solutions Difference Expert pharmacy benefit management (PBM) consulting team In-house pharmacists, PBM and Medicare Part D experts Former C-level PBM executives averaging 20+ years industry

More information

ORPHAN DRUGS MARKET ACCESS IN THE US. Doyle JJ, Sepulveda B, White C Quintiles Consulting, Hawthorne, NY, USA May 18, 2009

ORPHAN DRUGS MARKET ACCESS IN THE US. Doyle JJ, Sepulveda B, White C Quintiles Consulting, Hawthorne, NY, USA May 18, 2009 ORPHAN DRUGS MARKET ACCESS IN THE US Doyle JJ, Sepulveda B, White C Quintiles Consulting, Hawthorne, NY, USA May 18, 2009 Introduction FDA orphan disease designation: A drug to treat a rare disease/condition

More information

WORLD PREVIEW 2014, OUTLOOK TO 2020

WORLD PREVIEW 2014, OUTLOOK TO 2020 WORLD PREVIEW 2014, OUTLOOK TO 2020 June 2014 Welcome to the EvaluatePharma World Preview 2014, Outlook to 2020 The seventh edition of EvaluatePharma s World Preview brings together many of our analyses

More information

Prescription Drug Plan

Prescription Drug Plan Prescription Drug Plan The prescription drug plan helps you pay for prescribed medications using either a retail pharmacy or the mail order program. For More Information Administrative details and procedures

More information

MArch 2015. The 2014 Drug Trend Report MEDICAID

MArch 2015. The 2014 Drug Trend Report MEDICAID MArch 2015 The 2014 Drug Report MEDICAID content medicaid 3 Medicaid Year in Review A Look at Medicaid Overall Drug for 2014 Medicaid: Traditional Therapy Classes and Insights Top 10 Medicaid Traditional

More information

FREQUENTLY ASKED QUESTIONS ABOUT THE CVS CAREMARK PRESCRIPTION DRUG PROGRAM

FREQUENTLY ASKED QUESTIONS ABOUT THE CVS CAREMARK PRESCRIPTION DRUG PROGRAM FREQUENTLY ASKED QUESTIONS ABOUT THE CVS CAREMARK PRESCRIPTION DRUG PROGRAM ABBVIE EMPLOYEES WANT TO KNOW What s New in 2015? AbbVie is making changes in its pharmacy benefit program to ensure our medical

More information

Commercial Specialty Medication Research: 2016 Benchmark Projections

Commercial Specialty Medication Research: 2016 Benchmark Projections Commercial Specialty Medication Research: 2016 Benchmark Projections Prepared by: Katie Holcomb, FSA, MAAA Consulting Actuary Justin Harris, ASA, MAAA Associate Actuary 15800 Bluemound Road Suite 100 Brookfield,

More information

After a decade of relative stability as increasing use of

After a decade of relative stability as increasing use of RESEARCH BRIEF NO. 5 APRIL 2015 Rx Costs: A Primer for Health Care Advocates After a decade of relative stability as increasing use of generics significantly moderated spending, drug costs are set to increase

More information

www.oxfordhealth.com

www.oxfordhealth.com www.oxfordhealth.com Oxford s HMO products are underwritten by Oxford Health Plans (NY), Inc., Oxford Health Plans (NJ), Inc., and Oxford Health Plans (CT), Inc., and insurance products are underwritten

More information

PRESCRIPTION DRUGS: BACKGROUND AND BASICS

PRESCRIPTION DRUGS: BACKGROUND AND BASICS PRESCRIPTION DRUGS: BACKGROUND AND BASICS Medicare & Medicaid Briefings National Health Policy Forum January 30, 2009 Jim Hahn Congressional Research Service PRESCRIPTION DRUGS FAQS What is the price of

More information

Arthritis Foundation Position Statement on Biosimilar Substitution

Arthritis Foundation Position Statement on Biosimilar Substitution Arthritis Foundation Position Statement on Biosimilar Substitution The Affordable Care Act creates a regulatory pathway for the approval of a new generation of biologic medications called biosimilars.

More information

Specialty Pharmacy? Disclosure. Objectives Technician

Specialty Pharmacy? Disclosure. Objectives Technician Disclosure What s so SPECIAL about? I have no actual or potential conflict of interest in relation to this program/presentation. Michael DeCoske, PharmD, BCPS Associate Chief Pharmacy Officer Duke University

More information

2015 Travelers Prescription Drug Plan Blue Cross Blue Shield Plan and United Healthcare Choice Plus Plan

2015 Travelers Prescription Drug Plan Blue Cross Blue Shield Plan and United Healthcare Choice Plus Plan 2015 Travelers Prescription Drug Plan Blue Cross Blue Shield Plan and United Healthcare Choice Plus Plan Plan Details, Programs, and Policies Table of Contents Click on the links below to be taken to that

More information

Growth in revenue from MS drugs has been driven largely by price increases over the last several years.

Growth in revenue from MS drugs has been driven largely by price increases over the last several years. March 4, 2013 Ben Weintraub, PhD Are Injectable MS Drugs Finished? Market Ready for Tecfidera Companies: Biogen (BIIB) Sanofi (SNY) Teva (TEVA) Novartis (NVS) Merck Serono Bayer Schering Products: Tecfidera

More information

Summary. UnitedHealth Center for Health Reform & Modernization 1

Summary. UnitedHealth Center for Health Reform & Modernization 1 UnitedHealth Center for Health Reform & Modernization THE GROWTH OF SPECIALTY PHARMACY Current trends and future opportunities Issue Brief April 2014 Summary Innovative specialty drugs are providing important

More information

Express Scripts/Medco Prescription Plan Information For Drug Coverage Review, Prior Authorization Process and Personalized Medicine Information

Express Scripts/Medco Prescription Plan Information For Drug Coverage Review, Prior Authorization Process and Personalized Medicine Information Express Scripts/Medco Prescription Plan Information For Drug Coverage Review, Prior Authorization Process and Personalized Medicine Information The endowed health plan offers faculty and staff members

More information

Specialty Pharmacy. Oncology

Specialty Pharmacy. Oncology Specialty Pharmacy Oncology Background What are specialty drugs? Not an FDA designation No standard industry definition Categorized as: High cost (>$1,200 / month) Require special handling and administration

More information

Managed Care Pharmacy. Objectives. Health Plans Some Background 4/7/2015. Kim Moon, PharmD Spring 2015

Managed Care Pharmacy. Objectives. Health Plans Some Background 4/7/2015. Kim Moon, PharmD Spring 2015 Managed Care Pharmacy Kim Moon, PharmD Spring 2015 Objectives Describe the role of pharmacists in managed care plans Discuss the role of quality ratings systems in managed care pharmacy Explain some of

More information

Contents General Information... 1. General Information

Contents General Information... 1. General Information Contents General Information... 1 Preferred Drug List... 2 Pharmacies... 3 Prescriptions... 4 Generic and Preferred Drugs... 5 Express Scripts Website and Mobile App... 5 Specialty Medicines... 5 Prior

More information

2014 Prescription Drug Plan Annual Report February 27, 2015. Executive Summary

2014 Prescription Drug Plan Annual Report February 27, 2015. Executive Summary 2014 Prescription Drug Plan Annual Report February 27, 2015 Executive Summary Calendar Year (CY) 2014 was the 12th year of operation for the university s self-administered Prescription Drug Plan. Below

More information

Understanding Specialty Pharmacy Management and Cost Control

Understanding Specialty Pharmacy Management and Cost Control Understanding Specialty Pharmacy Management and Cost Control JUNE 2010 Defining Concern 3 Why It Is Important To Focus On Specialty Pharmacy 3 Definition of Specialty Drugs and Specialty Pharmacy Management

More information

2015 Prescription Drug Plan Annual Report March 2, 2016

2015 Prescription Drug Plan Annual Report March 2, 2016 2015 Prescription Drug Plan Annual Report March 2, 2016 Executive Summary Calendar year 2015 was the thirteenth year of operation for the university s self-administered prescription drug plan. In 2015,

More information

Prescription Solutions Specialty Pharmacy

Prescription Solutions Specialty Pharmacy May/June 2010 Prescription Solutions Specialty Pharmacy Utilization Management Programs Utilization management evaluates the appropriateness, clinical need and efficiency of prescription medications, based

More information

SPECIALTY DRUGS: IT S ABOUT HEALTH, VALUE AND PRICE

SPECIALTY DRUGS: IT S ABOUT HEALTH, VALUE AND PRICE SPECIALTY DRUGS: IT S ABOUT HEALTH, VALUE AND PRICE (OR, IF SPECIALTY DRUGS ARE SO COST EFFECTIVE, WHY CAN Y WE AFFORD THEM?) Sharon Levine MD June 11, 2015 What is a specialty drug? DefiniJons vary; different

More information

New York State Auto Dealers Association Group Insurance Trust (GIT) Prescription Drug Coverage Summary

New York State Auto Dealers Association Group Insurance Trust (GIT) Prescription Drug Coverage Summary New York State Auto Dealers Association Group Insurance Trust (GIT) Prescription Drug Coverage Summary Effective January 1, 2014, all pharmacy coverage will be administered by Express Scripts and its affiliates.

More information

PRESCRIPTION DRUG PLAN

PRESCRIPTION DRUG PLAN PRESCRIPTION DRUG PLAN The Plan Administrator will pay a portion of the cost of covered prescriptions. Maximum benefits are paid when prescriptions are filled through the CVS Caremark network pharmacies.

More information

Original Policy Date

Original Policy Date MP 5.01.20 Tysabri (natalizumab) Medical Policy Section Prescription Drug Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Local Policy/12:2013 Return to Medical Policy Index Disclaimer

More information

Specialty Drug Hyperinflation:

Specialty Drug Hyperinflation: Specialty Drug Hyperinflation: The Risk to Patients and the Health Care System Specialty drugs 1 offer important hope for many patients with complex, hard-to-treat illnesses. While the price of specialty

More information

The Evolving Landscape of Payment Care Delivery and Manufacturer Implications of Coverage Expansion

The Evolving Landscape of Payment Care Delivery and Manufacturer Implications of Coverage Expansion November 2013 Edition Vol. 7, Issue 10 The Evolving Landscape of Payment Care Delivery and Manufacturer Implications of Coverage Expansion By Gordon Gochenauer, Director, Oncology Commercial Strategies,

More information

New York Bio Conference 2016. Mark J. Alles Chief Executive Officer

New York Bio Conference 2016. Mark J. Alles Chief Executive Officer New York Bio Conference 2016 Mark J. Alles Chief Executive Officer Great Progress AGE 72 World Life Expectancy 2005-2014* 17 new drugs for rare diseases 71.5 71 Two new MS drugs First drug to target root

More information

Princeton University Prescription Drug Plan Summary Plan Description

Princeton University Prescription Drug Plan Summary Plan Description Princeton University Prescription Drug Plan Summary Plan Description Princeton University Prescription Drug Plan Summary Plan Description January 2015 Contents Introduction... 1 How the Plan Works... 2

More information

Coventry Health Care of Georgia, Inc. Coventry Health and Life Insurance Company

Coventry Health Care of Georgia, Inc. Coventry Health and Life Insurance Company Coventry Health Care of Georgia, Inc. Coventry Health and Life Insurance Company PRESCRIPTION DRUG RIDER This Prescription Drug Rider is an attachment to the Coventry Health Care of Georgia, Inc. ( Health

More information

Adapting Pharmaceutical Reimbursement Policies to Manage Spending on High-Cost Drugs

Adapting Pharmaceutical Reimbursement Policies to Manage Spending on High-Cost Drugs Adapting Pharmaceutical Reimbursement Policies to Manage Spending on High-Cost Drugs Elizabeth Docteur, Principal, Elizabeth Docteur Consulting Ruth Lopert, Deputy Director, Pharmaceutical Policy & Strategy

More information

Specialty drug program. Save time. Save money. Feel good.

Specialty drug program. Save time. Save money. Feel good. Specialty drug program Save time. Save money. Feel good. What are specialty drugs? Specialty drugs are used to treat serious or ongoing medical conditions such as multiple sclerosis, hemophilia, hepatitis

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Health Technology Appraisal Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure

More information

Prescription drug costs continue to rise at

Prescription drug costs continue to rise at Prescription Drugs Developing an Effective Generic Prescription Drug Program by John D. Jones Pharmacy benefit managers (PBMs) use a variety of pricing strategies. When employers have a thorough knowledge

More information

Below are some frequently asked questions that will provide you with valuable information.

Below are some frequently asked questions that will provide you with valuable information. Welcome to your prescription drug benefit administered by CVS Caremark. Your prescription benefit is designed to bring you quality pharmacy care that will help you save money. Below are some frequently

More information

Overview of the BCBSRI Prescription Management Program

Overview of the BCBSRI Prescription Management Program Definitions Overview of the BCBSRI Prescription Management Program DISPENSING GUIDELINES mean: the prescription order or refill must be limited to the quantities authorized by your doctor not to exceed

More information

Overview of the BCBSRI Prescription Management Program

Overview of the BCBSRI Prescription Management Program Definitions Overview of the BCBSRI Prescription Management Program DISPENSING GUIDELINES mean: the prescription order or refill must be limited to the quantities authorized by your doctor not to exceed

More information

GENERAL INFORMATION. With Express Scripts, you have access to:

GENERAL INFORMATION. With Express Scripts, you have access to: CONTENTS GENERAL INFORMATION... 1 PREFERRED DRUG LIST....2 PHARMACIES... 3 PRESCRIPTIONS... 4 GENERIC AND PREFERRED DRUGS... 5 EXPRESS SCRIPTS WEBSITE AND MOBILE APP... 5 SPECIALTY MEDICATIONS... 6 PRIOR

More information

Pharmaceutical sales in Canada have a 2.5 percent share of the global market, making th

Pharmaceutical sales in Canada have a 2.5 percent share of the global market, making th Industry Canada (/eic/site/icgc.nsf/eng/home) Home Industries and Business Canadian Life Science Industries Biopharmaceuticals and pharmaceuticals Pharmaceutical industry profile Life Science Industries

More information

Outpatient Prescription Drug Benefit

Outpatient Prescription Drug Benefit Outpatient Prescription Drug Benefit GENERAL INFORMATION This supplemental Evidence of Coverage and Disclosure Form is provided in addition to your Member Handbook and Health Plan Benefits and Coverage

More information

Building a Specialty Pharmacy Business. Kyle Skiermont, PharmD Director of Specialty/Infusion Operation Fairview Pharmacy Services

Building a Specialty Pharmacy Business. Kyle Skiermont, PharmD Director of Specialty/Infusion Operation Fairview Pharmacy Services Building a Specialty Pharmacy Business Kyle Skiermont, PharmD Director of Specialty/Infusion Operation Fairview Pharmacy Services Overview Agenda Brief overview of Fairview Barriers for hospital/health

More information

Michał Pilkiewicz Country Manager IMS Health Poland

Michał Pilkiewicz Country Manager IMS Health Poland The Pharmaceutical Market in Poland - government regulation, pricing and reimbursement of medicines, in particular What is the influence on the market situation? Michał Pilkiewicz Country Manager IMS Health

More information

RIDER ADDING PRESCRIPTION DRUG COVERAGE

RIDER ADDING PRESCRIPTION DRUG COVERAGE Group Health Incorporated (hereinafter referred to as GHI ) 441 Ninth Avenue New York, NY 10001 RIDER ADDING PRESCRIPTION DRUG COVERAGE RETAIL DRUG PROGRAM Deductible: Generic Drugs: Brand Name Preferred

More information

New York City Office of Labor Relations Employee Benefits Program/Municipal Labor Committee

New York City Office of Labor Relations Employee Benefits Program/Municipal Labor Committee New York City Office of Labor Relations Employee Benefits Program/Municipal Labor Committee PICA PRESCRIPTION DRUG PROGRAM Self-Injectable Medications Chemotherapy Medications Questions & Answers Last

More information

TABLE OF CONTENTS. Introduction...1. Chapter1 AdvancesinTreatment...2. Chapter2 MedicinesinDevelopment...11. Chapter3 ValueandSpending...

TABLE OF CONTENTS. Introduction...1. Chapter1 AdvancesinTreatment...2. Chapter2 MedicinesinDevelopment...11. Chapter3 ValueandSpending... CANCER TABLE OF CONTENTS Introduction...1 Chapter1 AdvancesinTreatment...2 Chapter2 MedicinesinDevelopment......11 Chapter3 ValueandSpending......15 Chapter4 Conclusion...22 INTRODUCTION Researchers and

More information

Biologics Biosimilars

Biologics Biosimilars Biologics Biosimilars Q u e st i o n s Po l i c y S a fe t y What are biosimilars? Biosimilars are sometimes incorrectly and inappropriately called generic versions of original biological medicines. But

More information

Health Insurance and Cancer Drug Reimbursement

Health Insurance and Cancer Drug Reimbursement Quality health plans & benefits Healthier living Financial well-being Intelligent solutions Health Insurance and Cancer Drug Reimbursement Michael Kolodziej, M.D., FACP National Medical Director, Oncology

More information

SAVINGS $1 TRILLION OVER 10 YEARS GENERIC DRUG SAVINGS IN THE U.S. (FOURTH ANNUAL EDITION: 2012)

SAVINGS $1 TRILLION OVER 10 YEARS GENERIC DRUG SAVINGS IN THE U.S. (FOURTH ANNUAL EDITION: 2012) SAVINGS $1 TRILLION OVER 10 YEARS GENERIC DRUG SAVINGS IN THE U.S. (FOURTH ANNUAL EDITION: 2012) EXECUTIVE SUMMARY One trillion dollars in health care savings over the past decade! A current rate of more

More information

April 30, 2009. The Honorable Edward M. Kennedy Chairman Committee on Health, Education, Labor, and Pensions United States Senate

April 30, 2009. The Honorable Edward M. Kennedy Chairman Committee on Health, Education, Labor, and Pensions United States Senate United States Government Accountability Office Washington, DC 20548 April 30, 2009 The Honorable Edward M. Kennedy Chairman Committee on Health, Education, Labor, and Pensions United States Senate Subject:

More information

Patient Assistance Program Primer

Patient Assistance Program Primer Patient Assistance Program Primer Suzanne Lepage Private Health Plan Strategist Suzanne Lepage Consulting Inc. Kitchener, Ontario The opinions expressed in this presentation are those of the speaker. The

More information

Prescription Drug Benefits

Prescription Drug Benefits Stryker s healthcare plan provides benefits for covered prescription drugs, including contraceptives, insulin and diabetic supplies. Benefits are paid for covered drugs that are medically necessary for

More information

Commercial Insight: Disease Modification in Rheumatoid Arthritis - Market awaits game changing therapies and strategies

Commercial Insight: Disease Modification in Rheumatoid Arthritis - Market awaits game changing therapies and strategies Brochure More information from http://www.researchandmarkets.com/reports/1504775/ Commercial Insight: Disease Modification in Rheumatoid Arthritis - Market awaits game changing therapies and strategies

More information

group insurance The Tiered Plan with Dynamic Therapeutic Formulary Why pay more than you have to for your prescription drugs?

group insurance The Tiered Plan with Dynamic Therapeutic Formulary Why pay more than you have to for your prescription drugs? group insurance The Tiered Plan with Dynamic Therapeutic Formulary Why pay more than you have to for your prescription drugs? The constantly increasing cost of prescription drugs makes it a challenge to

More information

MESSA Saver Rx PRESCRIPTION DRUG RIDER BOOKLET. Good Health. Good Business. Great Schools.

MESSA Saver Rx PRESCRIPTION DRUG RIDER BOOKLET. Good Health. Good Business. Great Schools. MESSA Saver Rx PRESCRIPTION DRUG RIDER BOOKLET Good Health. Good Business. Great Schools. MESSA Saver Rx Prescription Drug Program The MESSA Saver Rx Prescription Drug Program is made available by a Group

More information

Can an administrative drug claims database be used to understand claimant drug utilization?

Can an administrative drug claims database be used to understand claimant drug utilization? Can an administrative drug claims database be used to understand claimant drug utilization? By Elaine McKenzie, BSP, MBA, Consultant, TELUS Health Analytics Elaine McKenzie is a consultant who works with

More information

UHC Branded Specialty Pharmacy Program

UHC Branded Specialty Pharmacy Program UHC Branded Specialty Pharmacy Program Evolution to Implementation Jake Groenewold, Senior Vice President, UHC Doug Smith, PharmD, Senior Director, UHC Kevin Colgan, MA, FASHP, Corporate Director of Pharmacy,

More information

Monoclonal antibody (mab) products are currently a fast

Monoclonal antibody (mab) products are currently a fast Antibody Monoclonal Therapeutics Janice M. Reichert, Ph.D. Monoclonal antibody (mab) products are currently a fast growing category of drugs. Like antibodies produced naturally by the human immune system,

More information

Prescription Plan FAQ s

Prescription Plan FAQ s Prescription Plan FAQ s What is a specialty medication? Specialty medication is the term used to describe certain medications and a set of services designed to meet the particular needs of people who take

More information

2016 PHARMACY. Benefit Summary Book. RXSUMBK2016 www.fepblue.org

2016 PHARMACY. Benefit Summary Book. RXSUMBK2016 www.fepblue.org 2016 Benefit Summary Book RXSUMBK2016 www.fepblue.org REVIEW THIS SUMMARY BOOKLET TO LEARN HOW TO GET THE MOST FROM YOUR PRESCRIPTION BENEFIT. THIS INCLUDES INFORMATION ABOUT: n Your prescription drug

More information

Impact of Health Reform on Prescription Drugs

Impact of Health Reform on Prescription Drugs Impact of Health Reform on Prescription Drugs 1 Indirect Effects Increased Rx Volume = More Prescriptions! Page 2 Retiree Drug Subsidy (RDS) Before HCR Tax-Free Subsidy RDS as taxdeductible income After

More information

Towards a New Model of Delivery of Care

Towards a New Model of Delivery of Care Towards a New Model of Delivery of Care What can we do Different to Provide Better Delivery of Care? Algis Jovaisas, MD,FRCPC Division of Rheumatology University of Ottawa Current Modelsurrent Private

More information

2012 Health Meeting June 13-15, 2012

2012 Health Meeting June 13-15, 2012 2012 Health Meeting June 13-15, 2012 Session #89 TS: Specialty Drugs Michael Einodshofer, RPh, MBA Raulo S. Frear, Pharm.D. Jason Bradley Gomberg, FSA, MAAA, FCA Moderator Ashlee Mouton Borcan, FSA, MAAA

More information

Thrifty White Pharmacy 9/5/2014. Specialty Pharmacy. Specialty Pharmacy: The Opportunities and the Challenges

Thrifty White Pharmacy 9/5/2014. Specialty Pharmacy. Specialty Pharmacy: The Opportunities and the Challenges Specialty Pharmacy: The Opportunities and the Challenges MPhA Annual Conference September 12, 2014 Justin Heiser, PharmD Senior Vice President, Pharmacy Operations Specialty Pharmacy High cost and/or high

More information

Key Medicare Issues for Coverage and Reimbursement of Specialty Pharmaceuticals

Key Medicare Issues for Coverage and Reimbursement of Specialty Pharmaceuticals Background Paper July 2008 Key Medicare Issues for Coverage and Reimbursement of Specialty Pharmaceuticals Advances in biotechnology have brought many effective new treatments for serious and debilitating

More information

Commercial Insight: Cancer Targeted Therapies and Immunotherapies -Top monoclonal antibody brands will resist competitive pressures through to 2019

Commercial Insight: Cancer Targeted Therapies and Immunotherapies -Top monoclonal antibody brands will resist competitive pressures through to 2019 Brochure More information from http://www.researchandmarkets.com/reports/1314569/ Commercial Insight: Cancer Targeted Therapies and Immunotherapies -Top monoclonal antibody brands will resist competitive

More information

Transitioning to Express Scripts

Transitioning to Express Scripts Transitioning to Express Scripts Welcome to Express Scripts. We re pleased to announce that, beginning 1/1/2015 the City of Frisco prescription benefit will be managed by Express Scripts. Express Scripts

More information

REVISING SPECIALTY TIERS

REVISING SPECIALTY TIERS WHITE PAPER REVISING SPECIALTY TIERS PROTECTING MEDICARE PART D BENEFICIARIES FROM BURDENSOME COST SHIFTING Gary G., Michigan Gary thought he had his financial assistance grant set up to cover his out-of-pocket

More information

2014 Prescription Drug Schedule Humana Medicare Employer Plan

2014 Prescription Drug Schedule Humana Medicare Employer Plan 2014 Prescription Drug Schedule Humana Medicare Employer Plan Option 98 City of Newport News Y0040_GHHHEF3HH14 SECTION I - INTRODUCTION TO SUMMARY OF BENEFITS Thank you for your interest in the Humana

More information

Paul K. Wotton, Ph.D President and Chief Executive Officer May 2012 AMEX: AIS

Paul K. Wotton, Ph.D President and Chief Executive Officer May 2012 AMEX: AIS Paul K. Wotton, Ph.D President and Chief Executive Officer May 2012 AMEX: AIS Safe Harbor Statement This presentation may contain forward-looking statements which are made pursuant to the safe harbor provisions

More information

It Pays to Shop: Variation in Out-of-Pocket Costs for Medicare Part D Enrollees in 2016

It Pays to Shop: Variation in Out-of-Pocket Costs for Medicare Part D Enrollees in 2016 It Pays to Shop: Variation in Out-of-Pocket Costs for Medicare Part D Enrollees in 2016 Medicare Part D drug plans differ considerably in the drugs they list on their formularies, their use of formulary

More information

PHARMACY BENEFIT DESIGN CONSIDERATIONS

PHARMACY BENEFIT DESIGN CONSIDERATIONS PHARMACY BENEFIT DESIGN CONSIDERATIONS Is your pharmacy benefit designed for your employees or the big drug companies? The pharmacy (or prescription) benefit is one of the most sought after benefits by

More information

PRESCRIPTION DRUG RIDER. Beechcraft

PRESCRIPTION DRUG RIDER. Beechcraft PRESCRIPTION DRUG RIDER Beechcraft If You have Medicare or will become Eligible for Medicare in the next twelve (12) months, Federal law gives You choices about Your prescription drug coverage. Please

More information